Intuitive Surgical Performance degli utili passati
Criteri Il passato verificati 4/6
Intuitive Surgical ha registrato una crescita degli utili a un tasso medio annuo di 16.7%, mentre il settore Medical Equipment ha registrato utili in crescita a un tasso medio annuo di 15.3%. I ricavi sono stati in crescita a un tasso medio annuo di 14.7%. Il ritorno sul capitale proprio di Intuitive Surgical è 17.3% e ha margini netti di 28.4%.
Informazioni chiave
16.72%
Tasso di crescita degli utili
16.64%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.90% |
| Tasso di crescita dei ricavi | 14.68% |
| Rendimento del capitale proprio | 17.26% |
| Margine netto | 28.45% |
| Ultimo aggiornamento sugli utili | 30 Jun 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Jul 21
ISRG: Future Returns Will Rely On Procedure Utilization Outpacing Medtech Sector Rotation
Intuitive Surgical's updated analyst price target reflects a reset from $565.25 to $501.73, as analysts factor in slightly softer procedure growth expectations, modestly adjusted revenue growth assumptions, and a lower applied future P/E multiple despite stable to slightly higher modeled profit margins. Analyst Commentary Recent Street research on Intuitive Surgical points to a reset in expectations rather than a collapse in confidence.Seeking Alpha • Jul 17
Intuitive Surgical Q2: The Market Is Missing The Bigger Picture
Summary Intuitive Surgical, Inc. remains a compelling long-term compounder, with operational improvements and robust growth prospects despite recent market headwinds. ISRG delivered solid Q2 results: revenue and EPS beat estimates, da Vinci procedures grew 20%, and gross margin reached 70%, reinforcing ISRG's strong positioning. Current valuation near a 5-year low—~35x forward earnings—offers a more attractive entry point, with multiple compression creating a margin of safety. I maintain my Buy rating on ISRG, as secular trends, international expansion, and R&D investment support continued high-teens growth and defend strong moats. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 07
ISRG: Procedure Momentum And Sector Reset Will Drive 2026 Upside
Intuitive Surgical's analyst price target has been reduced by $32.56 to $717.44 as analysts temper fair value, revenue growth, and margin assumptions in light of lower utilization concerns, inflation headwinds, and a reset in medtech sector valuations. Analyst Commentary Recent research coverage on Intuitive Surgical shows a clear reset in expectations, but it also highlights that some bullish analysts still see meaningful long term potential in the stock, even as they factor in lower utilization and inflation pressures across medtech.
Aggiornamento narrativa • Jun 23
ISRG: Sector Reset And Recalls Will Temper Strong Utilization Outlook
Intuitive Surgical's internal fair value estimate has been revised slightly lower to about $413 from roughly $430, as analysts reflect a sector wide reset in price targets tied to lower procedure utilization expectations and tighter assumptions around future medical technology margins. Analyst Commentary Recent Street research around Intuitive Surgical points to a more cautious tone, even from generally constructive voices.Articolo di analisi • Jun 19
Intuitive Surgical (ISRG) Stock Could Be 23.6% Undervalued After Q1 da Vinci 5 Demand
Intuitive Surgical (ISRG) is back in focus after Q1 2026 data showed 431 da Vinci systems placed, a 17% year over year increase, with upgrades to the da Vinci 5 and higher leasing activity shaping hospital demand. See our latest analysis for Intuitive Surgical. Despite the Q1 2026 da Vinci 5 upgrade cycle and stronger leasing uptake, Intuitive Surgical’s short term share price momentum has softened, with the share price down 27.62% year to date but a 5 year total shareholder return of 34.91%...Aggiornamento narrativa • Jun 08
ISRG: Future Returns Will Depend On Procedure Utilization Outpacing Sector Rotation Headwinds
Intuitive Surgical's updated analyst price target has moved lower in line with a reset of fair value from $611.82 to $565.25, as analysts factor in a sector wide pullback in medtech valuations, slightly softer revenue growth assumptions, modestly adjusted discount rates, and a revised future P/E of 53.19 while still citing company specific earnings leverage and product positioning in their broader rationale. Analyst Commentary Recent research on Intuitive Surgical highlights a mix of optimism on long term growth potential and caution around sector specific headwinds and valuation reset.Aggiornamento narrativa • May 25
ISRG: Medtech Reset And Recalls Will Shape Future Risk Reward Balance
Intuitive Surgical's updated analyst price target edges down by about $3 to $430.05, as analysts factor in a slightly lower P/E multiple and modest tweaks to growth and margin assumptions in light of recent sector wide medtech valuation resets. Analyst Commentary Recent Street research around Intuitive Surgical has tilted more cautious, with several bearish analysts cutting price targets to reflect what they describe as a reset in medtech valuations, a slower year for product launches, and broader worries about healthcare utilization.Aggiornamento narrativa • May 04
ISRG: Policy Shifts And Platform Adoption Will Shape Balanced Risk Reward Profile
Analysts have trimmed the fair value estimate for Intuitive Surgical by about $8 to $433. This reflects a mix of reduced revenue growth assumptions, slightly different discounting and modestly lower future P/E expectations after a series of both price target cuts and upgrades across the Street.Aggiornamento narrativa • Apr 20
ISRG: Future Policy Shifts And Platform Adoption Will Shape Premium Multiple
Analysts have trimmed the price target for Intuitive Surgical by about $16 to reflect a slightly higher discount rate and lower assumed future P/E multiple, while maintaining expectations for double digit revenue growth and resilient profit margins supported by a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent Street research on Intuitive Surgical shows a mix of trimmed price targets and a few upgrades, with most of the action centered on valuation reset rather than drastic changes to fundamental views.Aggiornamento narrativa • Apr 05
ISRG: Procedure Expansion And Sector Recovery Will Drive 2026 Upside
Analysts have adjusted Intuitive Surgical's price targets in a mixed but generally constructive way, with revisions ranging from cuts at UBS to $550 and $570 to higher targets at firms like Goldman Sachs at $714 and Bernstein at $740. These changes reflect updated views on growth, margins, and the valuation framework around a future P/E near 65.5x.Aggiornamento narrativa • Mar 22
ISRG: Future Platform Adoption And Policy Shifts Will Shape Premium Multiple Sustainability
Intuitive Surgical's updated analyst price target edges lower to $457.50 from $464.58, as analysts balance slightly firmer revenue growth and profit margin assumptions with a modestly lower forward P/E multiple after a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent research updates on Intuitive Surgical show a mixed backdrop, with several firms trimming price targets even as others reiterate or lift their views.Aggiornamento narrativa • Mar 08
ISRG: Future Platform Adoption And Policy Shifts Will Test Premium Multiple Assumptions
The analyst price target for Intuitive Surgical has been trimmed slightly, with modest shifts in fair value and discount rate inputs as analysts balance lower targets from firms like UBS and Citi against higher targets tied to Dv5 driven growth assumptions and sector recovery themes cited by other firms. Analyst Commentary Recent research on Intuitive Surgical shows a split tape, with some firms lifting targets on the back of Dv5 related growth assumptions and sector recovery themes, while others trim targets and stress execution and valuation risks.
Nuova narrativa • Feb 28
ISRG Riding the Lightning
I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone.Aggiornamento narrativa • Feb 22
ISRG: Future Returns Will Hinge On Procedure Utilization Versus Sector Rotation Risk
We have raised our Intuitive Surgical fair value estimate by about $15 to $611.82 per share, as analysts factor in slightly higher revenue growth expectations tied to the Dv5 rollout and sector recovery, partly offset by modestly lower margin assumptions. Analyst Commentary Recent Street research around Intuitive Surgical reflects a mix of optimism about growth drivers such as the Dv5 rollout and capital spending trends, alongside more cautious views on valuation and policy risk.Aggiornamento narrativa • Feb 07
ISRG: Future Procedure And Platform Execution Will Test Premium Multiple Assumptions
Analysts nudged their price targets higher on Intuitive Surgical, with a modest fair value move to about $468 per share. They recalibrated assumptions around slightly lower revenue growth, higher profit margins, and a somewhat lower future P/E multiple, following a mix of recent target hikes and trims across the Street.Aggiornamento narrativa • Jan 24
ISRG: Procedure Expansion And Sector Rebound Will Support 2026 Upside
Our Intuitive Surgical fair value estimate edges up to $750 from $740 as analysts recalibrate their price targets around updated growth, margin, and P/E assumptions informed by recent research on procedure trends, Dv5 contributions, and sector re-rating. Analyst Commentary Bullish analysts have been revisiting their models around procedure volumes, adoption of the Dv5 platform, and sector valuation resets.
Aggiornamento narrativa • Jan 18
ISRG at FV
Update on Valuation (18.10.26) Over the next 5 years I calculate with (actual values from 18.01.26 , price/shr at 533 USD ): Revenue Growth p.a.: 12% (Currently at 14,7%) – we saw the peak of revenue growth with nearly 15%, now even 12% is sporty, but with the „abo like“ revenues from spare parts and software licences, based on a still growing bases of installed systems, realisitc. Profit Margin: 30% (currently at 28,6%) - because spare parts in general have more margin then system sales, and the sales out of spare parts is still growing.Aggiornamento narrativa • Jan 10
ISRG: Dv5 Platform Rollout And Rising Procedure Volumes Will Drive 2026 Upside
Analysts have lifted their fair value estimate for Intuitive Surgical to US$740 from US$675, reflecting higher expected profit margins and a somewhat lower future P/E multiple. This change is supported by recent target increases tied to the da Vinci 5 rollout, stronger procedure trends and a more constructive view on healthcare into 2026.Aggiornamento narrativa • Dec 24
ISRG: Elevated Expectations Will Expose Premium Pricing To Utilization And Margin Disappointments
Analysts have raised their price targets on Intuitive Surgical by roughly $50-$60 per share, citing stronger than expected Q3 revenue and EPS growth, improving profitability despite tariff and mix headwinds, and encouraging trends in system utilization that support a higher fair value of about $468 per share, even as valuation remains a key consideration. Analyst Commentary Recent Street research on Intuitive Surgical reflects a mix of optimism on the company’s operational momentum and caution around valuation and risk-reward.Aggiornamento narrativa • Dec 10
ISRG: Future Returns Will Depend On Utilization Strength Versus Sector Volatility
Analysts nudged their average price target on Intuitive Surgical higher by about $3 to roughly $596, citing stronger than expected Q3 profitability, robust demand, and encouraging utilization trends that more than offset lingering concerns about valuation and sector volatility. Analyst Commentary Analyst reactions to the quarter highlight a mix of optimism around execution and utilization trends alongside lingering concerns about valuation and sector sentiment.Aggiornamento narrativa • Nov 26
ISRG: Future Direction Will Balance Demand Strength Against Persistent Sector Volatility
Analysts modestly raised their price targets for Intuitive Surgical, with recent updates clustering in the $525 to $603 range. They cited stronger-than-expected quarterly results and robust demand supporting profitability, despite ongoing sector volatility.Aggiornamento narrativa • Nov 12
ISRG: Future Performance Will Depend On Execution Amid Competitive Pressures
The consensus analyst price target for Intuitive Surgical saw a modest revision, decreasing slightly by $1 to $592.96. Analysts cited solid Q3 performance, ongoing profitability, and mixed expectations around future risks and valuation.Aggiornamento narrativa • Oct 29
Rising Demand And Cost Pressures Will Shape Robotic Surgery Outlook
The analyst price target for Intuitive Surgical has been raised from $573.55 to $594.29. Analysts cite strong third-quarter earnings, improving profit margins, and robust demand, despite ongoing pressures and competitive risks.Aggiornamento narrativa • Oct 14
Emerging Markets Will Expand Robotic-Assisted Surgery Adoption
Analysts have slightly lowered their fair value estimate for Intuitive Surgical to $573.55 from $582.10. They cite mixed views on sales momentum and margin sustainability, despite ongoing strength in fundamentals and recent earnings.Articolo di analisi • Sep 09
The Returns At Intuitive Surgical (NASDAQ:ISRG) Aren't Growing
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...Seeking Alpha • Apr 18
Intuitive Surgical: Too Many Rain Clouds Coming
Summary Intuitive Surgical dominates the growing robotic surgery market with a 60% share, but faces rising competition from Medtronic and Johnson & Johnson. Intuitive Surgical's high valuation (P/E ratio of 60x) makes it less attractive for new investors. The company boasts high margins, no debt, and strong revenue growth, but faces short-term challenges like import tariffs and competitive pressures. While ISRG is fundamentally strong, I recommend waiting for a more attractive entry point due to current high valuations and market risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 11
Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)
Summary Intuitive Surgical stock outperformed the S&P 500 since September 2024, with Q4 revenue growing 25% year-over-year to $2.41 billion. The installed base of da Vinci surgical systems grew 15% to 9,902 units, with recurring revenue constituting 84% of total revenue. Management forecasts procedure growth slowing from 17% to 13-16% in 2025, with margin pressure expected due to various factors. Despite strong market position and growth, ISRG trades at multiples over four times its peers and appears considerably overvalued on DCF analysis. Read the full article on Seeking AlphaNuova narrativa • Mar 30
From Battle Field to Robotic Surgery
Intuitive Surgical (ISRG) is a pioneer in robotic-assisted surgery, revolutionizing the medical field with its da Vinci surgical system. Founded in 1995, the company has continuously innovated, makingNuova narrativa • Mar 18
Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth
Increased Adoption of Robotic Surgery:Hospitals and surgical centers continue to adopt Intuitive Surgical’s da Vinci systems as clinical evidence shows improved outcomes and reduced recovery times.ExpSeeking Alpha • Mar 09
Intuitive Surgical: Getting Closed To Its Fair Value
Summary Intuitive Surgical is going through a temporary decrease in margins and returns on capital, but as the investment cycle approaches its end, profitability will increase. The company has been heavily investing in expanding production, AI, machine learning, and augmented reality, but CapEx will decrease in 2025. The CEO owns ~70 times its total yearly compensation, so there is a strong alignment between management and shareholders. While the stock is slightly overvalued, there might be an opportunity soon to buy into this outstanding business. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Intuitive Surgical: The Robot Is Well-Oiled
Summary Intuitive Surgical, with its Da Vinci robots, enjoys a great competitive position in minimally invasive surgery, driven by $6 billion in R&D and first-mover advantage. The business model, with 84% recurring revenue from instruments, accessories, and services, ensures stable growth and high margins, despite occasional stock volatility. Financially, ISRG boasts zero debt and $8.8 billion in cash, but declining margins and high valuation multiples make current stock prices hard to justify. While ISRG's growth prospects are strong, the current valuation suggests limited returns; thus, I cannot rate it a buy but also not a sell. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Intuitive Surgical: Second Half 2025 Guidance Is Critical To Maintaining Current Euphoria
Summary Intuitive Surgical's share price surged after the company reported 25% YoY revenue growth in the fourth quarter. Despite macro headwinds, robust procedure volumes, international expansion and new product rollouts continue to support growth. While investors probably should look through the current growth surge, particularly given Intuitive's extreme valuation, near term earnings beats could continue to drive the stock higher. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Intuitive Surgical: Growing Impressively, But It Appears Overvalued
Summary Intuitive Surgical's da Vinci system shows strong growth and innovation, but current valuation warrants a Hold rating due to potential overvaluation risks. The global robotics market is expanding, driven by aging populations and demand for minimally invasive procedures, benefiting Intuitive Surgical's recurring revenue model. Despite impressive financial metrics and growth, high P/E ratio and EV/Sales suggest caution, with intrinsic value calculations indicating potential overvaluation. Regulatory approvals and AI advancements promise future growth, but economic shocks and competitive threats could impact market share and investor confidence. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Intuitive Surgical: One Of The Best Business Models In The World, But Not At This Price
Summary Intuitive Surgical's da Vinci systems revolutionize minimally invasive surgery, offering superior precision, dexterity, and visualization, leading to better patient outcomes and efficiency. The business model thrives on recurring revenue from disposable instruments and maintenance, ensuring long-term cash flow predictability and resilience. Despite high valuations, Intuitive Surgical's technological superiority, lack of competition, and robust R&D investment justify its premium market position. Given the current overvaluation, I recommend holding shares and waiting for market corrections before buying, projecting a target price of $495 per share by 2030. Read the full article on Seeking AlphaSeeking Alpha • Oct 18
Intuitive Surgical Q3: Da Vinci 5 Robot Set For 2025, But Overvalued
Summary I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth potential from innovative technology and positive surgeon feedback. Despite strong leadership and market position, ISRG's overvaluation and high WACC of 13% justify the 'Sell' rating. Key risks include potential stock repurchases and successful monetization of software, which could push the stock price higher in the future. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Intuitive Surgical Offers Low Risk, High Return Despite Valuation Concerns
Summary Intuitive Surgical remains a leader in robotic surgery despite intensifying competition from Medtronic and Johnson & Johnson. The company's da Vinci procedures grew 17% year-over-year, driving growth in system sales and recurring revenue. Intuitive Surgical reported strong Q2 2024 earnings, with $2.01 billion in revenue, surpassing analysts' estimates. The company's high valuation presents risk, though long-term prospects in the robotic surgery market remain favorable. I recommend a "buy" for ISRG due to its financial health, innovation in surgical robotics, and long-term growth outlook. Read the full article on Seeking AlphaRipartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Intuitive Surgical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 26 | 11,034 | 3,139 | 2,492 | 1,415 |
| 31 Mar 26 | 10,582 | 2,979 | 2,435 | 1,358 |
| 31 Dec 25 | 10,065 | 2,856 | 2,385 | 1,312 |
| 30 Sep 25 | 9,612 | 2,747 | 2,289 | 1,254 |
| 30 Jun 25 | 9,145 | 2,608 | 2,248 | 1,210 |
| 31 Mar 25 | 8,715 | 2,476 | 2,212 | 1,177 |
| 31 Dec 24 | 8,352 | 2,323 | 2,140 | 1,145 |
| 30 Sep 24 | 7,867 | 2,243 | 2,095 | 1,111 |
| 30 Jun 24 | 7,573 | 2,094 | 2,036 | 1,074 |
| 31 Mar 24 | 7,319 | 1,988 | 1,975 | 1,038 |
| 31 Dec 23 | 7,124 | 1,798 | 1,964 | 999 |
| 30 Sep 23 | 6,851 | 1,517 | 1,863 | 983 |
| 30 Jun 23 | 6,665 | 1,425 | 1,847 | 951 |
| 31 Mar 23 | 6,431 | 1,312 | 1,801 | 913 |
| 31 Dec 22 | 6,222 | 1,322 | 1,712 | 879 |
| 30 Sep 22 | 6,118 | 1,378 | 1,673 | 818 |
| 30 Jun 22 | 5,964 | 1,435 | 1,600 | 767 |
| 31 Mar 22 | 5,906 | 1,644 | 1,532 | 722 |
| 31 Dec 21 | 5,710 | 1,705 | 1,467 | 671 |
| 30 Sep 21 | 5,489 | 1,689 | 1,370 | 637 |
| 30 Jun 21 | 5,163 | 1,623 | 1,305 | 627 |
| 31 Mar 21 | 4,551 | 1,173 | 1,234 | 608 |
| 31 Dec 20 | 4,358 | 1,061 | 1,216 | 595 |
| 30 Sep 20 | 4,307 | 1,053 | 1,227 | 602 |
| 30 Jun 20 | 4,358 | 1,136 | 1,220 | 583 |
| 31 Mar 20 | 4,604 | 1,386 | 1,213 | 560 |
| 31 Dec 19 | 4,479 | 1,379 | 1,178 | 557 |
| 30 Sep 19 | 4,247 | 1,314 | 1,121 | 521 |
| 30 Jun 19 | 4,040 | 1,210 | 1,053 | 492 |
| 31 Mar 19 | 3,850 | 1,147 | 998 | 467 |
| 31 Dec 18 | 3,724 | 1,128 | 941 | 418 |
| 30 Sep 18 | 3,570 | 804 | 876 | 385 |
| 30 Jun 18 | 3,457 | 810 | 847 | 361 |
| 31 Mar 18 | 3,306 | 778 | 820 | 351 |
| 31 Dec 17 | 3,138 | 671 | 811 | 329 |
| 30 Sep 17 | 3,003 | 906 | 762 | 311 |
| 30 Jun 17 | 2,878 | 819 | 736 | 290 |
| 31 Mar 17 | 2,790 | 780 | 712 | 260 |
| 31 Dec 16 | 2,707 | 738 | 692 | 240 |
| 30 Sep 16 | 2,619 | 722 | 666 | 223 |
| 30 Jun 16 | 2,522 | 678 | 653 | 212 |
| 31 Mar 16 | 2,434 | 628 | 643 | 206 |
| 31 Dec 15 | 2,367 | 589 | 627 | 197 |
| 30 Sep 15 | 2,285 | 546 | 621 | 192 |
Guadagni di qualità: ISRG ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di ISRG (28.4%) sono inferiori rispetto allo scorso anno (28.5%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di ISRG sono cresciuti del 16.7% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di ISRG nell'ultimo anno ( 20.4% ) supera la media quinquennale ( 16.7% all'anno).
Guadagni vs Settore: La crescita degli utili ISRG nell'ultimo anno ( 20.4% ) ha superato la percentuale del settore Medical Equipment 14.8%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 17.3% ) di ISRG è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/24 01:48 |
| Prezzo dell'azione a fine giornata | 2026/07/23 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Intuitive Surgical, Inc. è coperta da 54 analisti. 31 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| null null | Argus Research Company |
| David Rescott | Baird |